Latest news with #SouthernStar
Yahoo
23-05-2025
- Business
- Yahoo
Silver Star Properties REIT, Inc. Releases Exclusive Podcast Interview with former General Counsel Adrienne Collins
HOUSTON, May 23, 2025 /PRNewswire/ -- Silver Star Properties REIT, Inc. ("Silver Star" or the "Company"), a self-managed real estate investment trust currently repositioning into the self-storage asset class, is pleased to announce the release of a new episode of its Silver Star Podcast featuring Adrienne Collins, former General Counsel, Chief Compliance Officer, and Corporate Secretary of the Company. The episode, hosted by Gerald W. Haddock, CEO and Executive Chairman, highlights Collins' significant contributions during a pivotal period of restructuring and recovery for the Company. In this interview, Adrienne Collins discusses her crucial role at Silver Star, particularly after the company emerged from bankruptcy. She outlines the significant challenges she faced, including resolving 401(k) issues, dealing with deferred maintenance on real estate assets, and navigating difficult negotiations with lenders. Adrienne shares insights into the company's reputation before and after bankruptcy, her approach to restoring professionalism, and her work to position Silver Star for success in the public markets. Despite facing adversity, she reflects on her efforts to stabilize the company, build relationships with key stakeholders, and tackle complex problems with determination and expertise. The podcast is now available on our website at Transcript of the podcast can be found at Forward-Looking Statements: This press release contains a number of forward-looking statements. Because such statements include a number of risks, uncertainties, and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements, and investors should not place undue reliance on any such statements. Forward-looking statements can often be identified by words such as "continues," "can," expect," "intend," "will," "anticipate," "estimate," "may," "plan," "believe" and similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding the Company's search for a new auditor and its hope that a new auditor can be engaged in the near future and that its annual report on Form 10-K can be completed and publicly filed; the continuation of the examination of the current operations of Southern Star; the Company's intent to consider various alternatives, including the possible sale of Southern Star, the sale of specific assets within individual DSTs and dissolution of the respective trusts, and/or the outsourcing of various aspects of Southern Star's operations; the Company's plan to update investors with respect to the status of Southern Star as appropriate; the Company's expectations and beliefs regarding the Hartman litigation; the timing and ultimate resolution of the various litigation, fight for corporate control and other matters involving Hartman; the continued execution of the Company's strategy of pivoting into the self-storage space; the Company's continual evaluation of its legacy assets in order to maximize shareholder value; the Company's policy to not dispose of any asset for less than its maximum determinable value and to maximize earnings and value; the implications to the Company of the assignment of an OTC trading symbol for its common stock; whether the Company may be subject to certain FINRA rules; any actions the Company may need to take to comply with any FINRA rules; the Company's continual evaluation of various options to provide greater shareholder liquidity, including its intention to seek listing of its common stock on a securities exchange or admission to over-the-counter trading, a public offering, a listing of the common stock on an exchange or admission to OTC trading without a public offering, and merger and/or acquisition opportunities; the Company's belief that further legal action could ensue to unwind the issuance of common shares under the Rights Plan if Hartman prevails in his efforts to set aside or invalidate the Rights Plan or to cause the dilutive issuance of additional common shares to Hartman, as well as any further action Hartman may take to prevent other Company shareholders from receiving benefits under the Rights Plan. None of the foregoing are guarantees or assurances of future outcomes or results and all are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. A number of important factors could cause actual results to differ materially from the forward-looking statements contained in this material. Forward-looking statements in this press release speak only as of the date on which such statements were made, and the Company undertakes no obligation to update any such statements that may become untrue because of subsequent events. Such forward-looking statements are subject to the safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. View original content to download multimedia: SOURCE Silver Star Properties REIT Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Examiner
24-04-2025
- Business
- Irish Examiner
Older world feel in great spot
THERE'S a lovely, older world feel to No 1 Vandeville, a period era end-terrace home at the start of Cork city's Ballinlough Road. It's near St Finbarr's Hospital, the reinvigorated bar the Southern Star, new cafes at Capwell Road and Bellair Estate, a Tesco Express, and is a 10- or 15-minute walk to the city centre: its location knocks it out of the park for southside, easy suburban convenient living. Likely to date to about 1900, it's the first of a terrace of four compact charmers, each with railed front gardens, bay windows, slate roof, and red brick chimneystacks, and it's the only one of the four with side access to its rear garden. It's new to market with estate agent James G Coughlan, with a €360,000 AMV: that's what nearby No 4 went up for sale at, back in 2019 when it featured in these pages, and it sold by early 2020 for a recorded €352,000. Time has moved on in the near-five years since, as has the market, but the pricing is at this similar point because No 4 had had slight extension work and general upgrades done to it, with size put at 1,1,00 sq ft when it appeared in these pages. In contrast, No 1 is put at just 66 sq m or just over 700 sq ft, by Jim Coughlan, and he adds that it needs modernisation: it comes with an E2 BER right now (No 4 was similar, with an E1 BER.) Nos 1 and 2 have original sash windows, looking lovely in their bays, and from the front door in No 1 has loads of original features, hall tiling, varnished floors, stripped pine doors, and original fireplaces too, in the front living room and in all three bedrooms. It's got black period style central heating radiators and the bath is a huge cast iron one, with green enamel inside and a looped shower curtain above. 'This gem will appeal to the discerning buyer who is looking for something timeless and different,' says Mr Coughlan adding that it's got a great back garden (running back along one of the two entrances to Marble Hall Lawn) with gated side access from its railed front. VERDICT: Loads of originality.
Yahoo
13-02-2025
- Business
- Yahoo
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources. SAN ANTONIO, Feb. 13, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the biotechnology contract research organization (CRO) industry and, based on its findings, recognizes Southern Star Research with the 2024 Asia-Pacific Competitive Strategy Leadership Award. The company is a full-service CRO specializing in guiding sponsors through the intricate process of bringing new medical products to market. Southern Star is a vital intermediary between small biotech companies in North America and Europe and clinical trial sites in Australia. Starting with a team of three, the company successfully conducted its first clinical trial in the cardiovascular sector and has expanded into an international team of specialists managing studies across the globe. Southern Star offers comprehensive support for early-phase clinical trials, leveraging its extensive expertise and strong industry relationships for safe and efficient trial initiation. It also offers comprehensive clinical operations, expert biometrics, safety and medical monitoring, medical writing services, and later-phase clinical trials across the APAC region. Southern Star positions itself as a service provider and a trusted ally, focusing on personalized support rather than transactional relationships. This approach distinguishes it from larger CROs and pharma companies, which prioritize volume over individual client needs. The company leverages a combination of cost-effectiveness, high-quality outcomes, and reduced regulatory bureaucracy in Australia to deliver swift and effective solutions that allow biotech firms to bring their products to market more efficiently. Southern Star employs strategic partnerships and a focused approach for effective clinical trial management, particularly in later phases. Recognizing that biotech firms and small pharma companies often prefer a one-stop shop for their Phase 3 trials, the company collaborates with various laboratories. These strategic alliances enable Southern Star to act as a comprehensive outsourced solution for clients—a capability that enhances its attractiveness to biotechs seeking a streamlined study process as it gives them access to necessary lab services through a trusted partner. Ojaswi Rana, best practices research analyst at Frost & Sullivan, observed, "Southern Star's commitment to customer value chain compression expertly reduces trial complexity and accelerates time-to-market for new medical products. By offering seamless, integrated solutions across all phases of clinical trials, the company improves efficiency and ensures that sponsors meet regulatory demands while optimizing resources. This strategic approach shortens development timelines significantly, providing sponsors with a clear competitive advantage in bringing innovative therapies to market swiftly and cost-effectively." Southern Star's dedication to employing only local staff sets it apart from many competitors, a strategy critical for maximizing the Australian government's research and development (R&D) tax incentives. The company employs highly specialized statisticians and maintains close relationships with them, giving it an edge over competitors who often struggle to find and retain such talent. Ensuring that all necessary skills are sourced locally enables Southern Star to provide high-quality services while remaining compliant with government regulations regarding tax incentives. By setting itself apart in a competitive landscape, Southern Star achieves exceptional client satisfaction and positions itself as a vital ally in navigating the complexities of clinical trials and ultimately driving successful outcomes. It employs a proactive, relationship-driven approach that emphasizes trust and personal connection. Its pivotal differentiation element is the profound trust established between the company and its clients. "Southern Star minimizes bureaucratic hurdles, reduces the number of steps in the customer journey, and accelerates the timeline from trial initiation to results reporting. Furthermore, it strategically aligns its operations with transformative megatrends, such as the expedited regulatory changes prompted by the COVID-19 pandemic. This alignment positions the company to capitalize on new opportunities and improve operational efficiency, solidifying its status as a critical player in the dynamic biotech industry," added Ojaswi. With its strong overall performance, Southern Star earns Frost & Sullivan's 2024 Asia-Pacific Competitive Strategy Leadership Award in the biotech CRO industry. Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning, and customer satisfaction. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion. Contact: Tarini SinghE: About Southern Star Research Southern Star Research is a full-service Contract Research Organization (CRO) dedicated to navigating the complexities of bringing new medical products to market. With a legacy of excellence that began 14 years ago in Sydney, we have grown from a small, passionate team into a global network of experts committed to delivering high-quality services in medical writing, clinical monitoring, project management, biostatistics, data management, safety and medical monitoring, and quality assurance. Southern Star Research has been recognized for its outstanding contributions to the field, winning prestigious awards such as the Frost and Sullivan 2024 Asia-Pacific Competitive Strategy Leadership Award and being named as Great Place to Work in Australia in 2024. Our international team continues to deliver innovative clinical trial solutions across diverse therapeutic areas, ensuring the success of every study we manage. SOURCE Frost & Sullivan
